Good humorous post! A good change in an otherwise boring board. Thanks, Short!!
Just be careful that the WS dogs don't get you!!
I think all solid-tumor trials will have to go for longer-duration side-effect studies than for hematological applications. Also, those applications may require use of other inhibitors besides Imetelstat. Thus, I treat success in solid-tumor trials farther in the future. Yes, positive indications in some will begin showing up much earlier (along with some genetic-marker studies) and, hence, expectation will build up gradually.
In any case, the immediate success apparently will come from application to MF, MDS and AML. The market for these three by itself is substantially large. It remains to be seen what avenues Geron management will find to indulge itself in the solid tumor trials. I expect a compatible merger with a big pharma to be inevitable.
Do Street's positive signals foresee such big-boy upgrades? The time for Tefferi's additional data, announcement for Geron's Ph 2 MF trial, and some indication for the Asteria deal is fast coming along with the fast track status - all hardly a few weeks from now. Yes, the WS dogs will find this to be an opportune time.
I am accumulating at this point!! After Rabin was let go, something better must evolve in the coming months.
Thanks, Scistats. Although old, this is a significant lab observation. I am sure, Tefferi is aware of this and is looking for other combinations with GRN163 for wider clinical applications to solid-tumor cases. Of course, Scarlett and company gave up on it after Geron's own trial on lung cancer; it's sad to note that those idiots did not dig deep enough. That work now must have been in Tefferi's plans.
If you look at Exelixis's Cabozintinib, similar thing happened and Exelixis management is now looking into wider applications of Cabo. The difference between EXEL and GERN is that, EXEL has a board of advisers that consists of well-known experts, GERN's management is too arrogant to have that wisdom!! GERN could not have been where it's to-day without Tefferi's help!!! Thank God, we shareholders are lucky that Tefferi participated.
WS dogs typically drag SP down to the bottom before a huge spike up! Time to add more!!
I think Tefferi may just repeat what he presented at the Scripps. He may add a note to push Imetelstat for expediting licensing and availability to acutely suffering patients.
There is a liability issue if the company provides the drug before a formal license. Of course, the physician prescribing it is more liable of malpractice allegation despite all the needed paper work and patient authorization he may get. Lawyers have a way to blame both and, often, they win or get settlement. Our legal system can screw both the physician and the drug supplier!! Note that our laws and regulations are instituted by our legislators who (including our Presidents, except Carter and Ike) have been almost all bloody lawyers and they have made laws to perpetuate their profession!! This legal difficulty has made life difficult for all businesses.
Maine, if you do well-controlled trading and wisely, you do not loose. I am not a trader (I do not need to); but, doing wisely and in a controlled manner is better in the current times (unlike in the past) instead of blindly holding long,
Yes 77, BM's strategy makes sense. Of course, you have to keep buying back more and more with the profits you make through trading cycles while keeping close watch of the events unfolding in such a way that you are in when big spikes occur. This will frustrate WS dogs who want to squeeze more shares from you. Yes, you have to be smart not to fall prey in their game.
Carolyn, Geron is located in CA, not in DE or NY City like Incyte and perhaps that's why it doesn't have WS dogs chasing it!! Look at PLUG; it's flying and Incyte still maintaining its SP above $60, despite everybody's knowledge now that Imetelstat sodium is going to outdate Jakafi pretty soon!!
Despite that blockbuster product, no debt, $150+M cash in hand, low annual burn-rate (staff of only ~40), and strong possibility of wider applications for Imetelstat, the SP is HESITATING nervously around $5 and below. The management's CCs and eyepoping presentation by Tefferi hasn't helped. The biggest mistake the management perhaps made recently was retaining those four WS firms and giveaway 22M +3M shares well below the going share price. That was an unexplained stupidity. But that did not cause share selloff; in fact, the shares were found to be in short supply!! Yet, several weeks after that offering and the share shortage, the SP still hovers around $5 and doesn't even hit value past $5.30 or there about. This is unusual and, to me, it's certainly a game of the WS dogs.
What these dogs may be doing is to corner more shares by shaking off retail and other institutional holders who want to seek greener pastures available elsewhere now. One thing they may be making a mistake about not being aware is that: The retail long holders of Geron shares are not stupid, are very well aware of the golden egg they are sitting on, are simply going to add more when the price hits low and are not going to be shaken off. Expectation of the dogs thus may be failing and, hence, are using all desperate means they can employ. I think that's what we are seeing in Geron shares trading.
The four WS firms got 3.3 million shares almost free of cost as a part of the last offering deal!! Perhaps they are playing this cat and mouse game using those shares to keep a lid on the SP so that a big-pharma client of theirs can gobble up Geron a bit cheaply? Is that the game? perhaps a strange world of WS!!!